Starting a GLP-1 medication is an exercise in uncertainty. You know side effects are likely — clinical trial data makes that clear — but what you really want to know is when they start, when they peak, and when they go away. This guide lays out the timeline based on data from the STEP, SURMOUNT, SUSTAIN, and ATTAIN clinical trial programs, combined with real-world patient reporting.
The pattern is remarkably consistent across semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), and orforglipron (Foundayo): GI side effects dominate early, peak during dose escalations, and improve significantly by month 3–4 for most patients.
Week 1: The Introduction
The first week on a GLP-1 is when your body meets the drug for the first time. Side effects during week 1 are generally mild to moderate because you start at the lowest dose:
- Nausea: Affects 15–20% of patients in the first week. It is usually described as a low-grade queasiness, not severe vomiting. It tends to be worse in the first 2–3 days and then partially improves.
- Reduced appetite: This is technically the intended effect, but it can feel dramatic. Many patients report that food simply becomes less interesting within the first 3–5 days.
- Fatigue: Reported by 5–10% of patients. Often related to reduced caloric intake rather than a direct drug effect.
- Mild headache: 3–5% of patients. Usually resolves within a few days.
- Injection site reactions (injectable GLP-1s): Mild redness or itching at the injection site in ~2% of patients.
What is normal: Mild nausea, reduced hunger, slightly less energy. What is not normal: Severe vomiting, inability to keep fluids down, abdominal pain radiating to the back.
Weeks 2–4: Settling In at Starting Dose
By weeks 2–4, most patients experience some adaptation to the starting dose:
- Nausea: Typically improves by 30–50% compared to week 1. Many patients notice that nausea comes in waves rather than being constant — often worse after eating too much or eating high-fat foods.
- Constipation: Begins to emerge as a significant side effect during this period (10–15% of patients). GLP-1s slow gastric emptying, which affects the entire GI tract. Increased water and fiber intake helps.
- Bloating/gas: Reported by 5–10% of patients. Related to delayed gastric emptying.
- Weight loss begins: Most patients lose 2–5 pounds in the first month at the starting dose. This is a combination of reduced caloric intake and some water weight loss.
- Taste changes: An underreported side effect — approximately 5% of patients notice that certain foods (especially sweets and fried foods) taste different or less appealing.
The first month at the starting dose is about establishing tolerance. Your provider is watching to see if you can tolerate the drug before escalating.
Month 2: The First Dose Escalation
Most GLP-1 titration protocols call for a dose increase at week 4 or week 5. This is when many patients experience a resurgence of side effects:
- Nausea returns or worsens: 25–35% of patients report nausea after the first dose increase. It is typically more intense than the initial starting-dose nausea but shorter-lived (3–7 days).
- Diarrhea: 10–15% of patients. Usually resolves within 1–2 weeks. More common with semaglutide than tirzepatide.
- Constipation worsens: For patients already constipated, the dose increase can intensify it. Stool softeners and increased water intake become important.
- Acid reflux (GERD): 5–10% of patients notice increased reflux. Eating smaller meals and avoiding lying down after eating helps.
- Weight loss accelerates: Expect 3–6 additional pounds lost during month 2. The dose increase enhances appetite suppression and may improve glucose metabolism.
Key insight: The pattern of side effects returning with each dose escalation is expected and normal. It does not mean the drug is getting worse — it means your body needs time to adapt to each new dose level.
Months 3–4: The Turning Point
Months 3–4 represent the inflection point for most patients. This is when side effects begin to meaningfully improve for the majority:
- Nausea: Drops to 8–12% prevalence by month 3 (down from 25–35% during dose escalations). Most patients who still have nausea describe it as mild and intermittent.
- Constipation: Stabilizes for most patients. Those who developed management strategies (water, fiber, stool softeners) in months 1–2 typically have it well controlled.
- Diarrhea: Usually resolved by month 3 unless triggered by specific dietary choices.
- Energy levels normalize: Fatigue reported in the first month usually resolves completely. Many patients report feeling more energetic than baseline, likely related to improved metabolic health and weight loss.
- Additional dose escalation side effects: If your protocol calls for additional dose increases in months 3–4, expect a milder version of the month 2 pattern. Each subsequent escalation tends to produce less severe side effects than the previous one.
- Weight loss: Cumulative weight loss typically reaches 8–12% by month 4 on semaglutide, and 10–15% on tirzepatide.
Who Still Has Significant Side Effects at Month 3
Approximately 5–8% of patients continue to experience troublesome GI side effects at month 3–4 despite dose adjustments. Risk factors include:
- History of gastroparesis or slow gastric motility
- Pre-existing GERD
- Rapid dose escalation (skipping the slow titration)
- Eating patterns that conflict with the drug's mechanism (large meals, high-fat foods)
For these patients, strategies include holding at a lower dose for longer, adjusting meal size and composition, and in some cases switching between GLP-1 agents (e.g., from semaglutide to tirzepatide or vice versa).
Months 5–6: The New Normal
By months 5–6, most patients have reached or are approaching their target dose, and the side effect profile has largely stabilized:
- GI side effects: Reported by fewer than 10% of patients at maintenance doses. When they occur, they are typically mild and manageable.
- Appetite: The dramatic appetite suppression of the first few months moderates somewhat. Patients still eat less than baseline but no longer feel the extreme early fullness of the initiation phase.
- Weight loss rate: Begins to plateau for some patients. This is normal — the steep weight loss curve of months 1–4 gives way to a more gradual trajectory.
- Hair thinning: Approximately 3–5% of patients notice increased hair shedding around months 4–6. This is telogen effluvium, caused by rapid weight loss rather than the drug itself, and is usually temporary.
- Muscle loss concerns: Without adequate protein intake and resistance exercise, some weight lost will be lean mass. By month 6, body composition becomes an important focus.
Side Effect Percentages by Medication
| Side Effect | Semaglutide (Ozempic/Wegovy) | Tirzepatide (Mounjaro/Zepbound) | Orforglipron (Foundayo) |
|---|---|---|---|
| Nausea | 44% (peaks weeks 1–8) | 29% (peaks weeks 1–8) | 34% (peaks weeks 1–6) |
| Diarrhea | 30% | 21% | 19% |
| Vomiting | 24% | 12% | 15% |
| Constipation | 24% | 17% | 14% |
| Abdominal pain | 20% | 13% | 11% |
| Headache | 14% | 9% | 8% |
| Fatigue | 11% | 7% | 6% |
| GERD/dyspepsia | 9% | 10% | 7% |
| Discontinuation due to side effects | 7% | 4% | 5% |
Data from STEP, SURMOUNT, and ATTAIN clinical trial programs. Percentages represent patients reporting each side effect at any point during the trial, not necessarily ongoing.
How to Navigate Each Phase
- Weeks 1–2: Eat smaller meals. Hydrate aggressively. Avoid greasy or heavy foods. Keep ginger tea or ginger chews available for nausea.
- Weeks 3–4: If constipation develops, add a fiber supplement and increase water to 80+ oz/day. A daily stool softener is not a sign of failure.
- Dose escalation periods: Plan to eat lightly for 3–5 days after each dose increase. Some patients find it helpful to escalate on a Friday to have the weekend to adjust.
- Months 3–4: If side effects persist, talk to your provider about holding at the current dose for an additional 4 weeks before escalating. Slower titration often resolves persistent GI issues.
- Months 5–6: Shift focus to protein intake (aim for 0.7–1.0g per pound of lean body mass) and resistance training to preserve muscle mass during continued weight loss.
When Side Effects Are Not Normal
Most GLP-1 side effects are uncomfortable but not dangerous. However, some symptoms warrant immediate medical attention. See our guide to serious GLP-1 side effects for a complete list, but call your doctor immediately if you experience:
- Severe abdominal pain that radiates to your back (possible pancreatitis)
- Inability to keep any fluids down for more than 24 hours
- Signs of severe dehydration (dark urine, dizziness, rapid heartbeat)
- Neck swelling or difficulty swallowing (thyroid concern)
- Jaundice (yellowing of skin or eyes — possible gallbladder issue)
Bottom Line
The GLP-1 side effect timeline follows a predictable arc: worst during the first month and after each dose escalation, significantly better by month 3–4, and well-managed by month 5–6. The majority of patients who make it through the first 8–12 weeks find that side effects become background noise. The key is setting realistic expectations, using practical management strategies, and communicating with your provider about your titration pace.
For medication-specific side effect guidance, see our complete GLP-1 side effects guide and our Foundayo side effects breakdown.